NCT02685267View on ClinicalTrials.gov

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Prostate Cancer
Interventions
DRUG

Docetaxel

DRUG

Enzalutamide

DRUG

Prednisone

Trial Locations (5)

14263

Roswell Park Cancer Institute, Buffalo

53705

Univesity of Wisconsin, Madison

60201

NorthShore University HealthSytem - Kellogg Cancer Center, Evanston

60637

The University of Chicago, Chicago

62526

Decatur Memorial Hospital, Decatur

Sponsors

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

University of Chicago

OTHER

collaborator

Astellas Pharma Inc

INDUSTRY

lead

Prostate Cancer Clinical Trials Consortium

OTHER

NCT02685267 - Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter